New hope for rare cholesterol disease: can evinacumab shrink dangerous plaque?

NCT ID NCT07447648

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows about 52 people with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol and early heart disease. Researchers will compare those who get evinacumab (a cholesterol-lowering antibody) added to their usual treatment against those on standard therapy alone. Using CT scans of the heart, they will measure changes in artery plaque over 18-24 months to see if evinacumab helps stabilize or reduce plaque buildup.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

evinacumab (a lab-made antibody that lowers cholesterol by blocking a protein called ANGPTL3)

What this could lead to

If successful, this study could show that adding evinacumab to standard treatment helps slow or shrink dangerous artery plaque in people with HoFH, pointing toward better long-term heart health.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. It is also small (52 people) and early-stage, so findings may not apply to everyone or lead to immediate changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular disorder homozygous familial hypercholesterolemia Lipid Metabolism Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam University Medical Center, Amsterdam UMC, locatie AMC

    RECRUITING

    Amsterdam, Netherlands

    Contact Email: •••••@•••••

    Contact

  • Centro per le Malattie Rare del Metabolismo dei Lipidi, Unità di Medicina Interna e Malattie Metaboliche, Dipartimento di Medicina Traslazionale e di Precisione Sapienza, Università di Roma

    RECRUITING

    Roma, Italy

    Contact Email: •••••@•••••

    Contact

  • DAI di Medicina Clinica, Centro di Riferimento Regionale di Lipidologia e Dislipidemie, AOU Federico II di Napoli

    RECRUITING

    Naples, Italy

    Contact Email: •••••@•••••

    Contact

  • Dipartimento Scienze-Cardiovascolari, AO "Sant'Anna e San Sebastiano" di Caserta

    RECRUITING

    Caserta, Italy

    Contact Email: •••••@•••••

    Contact

  • Ege University,Director of Lipid and Prevention Clinic, Department of Cardiology

    RECRUITING

    Bornova, Turkey (Türkiye)

    Contact Email: •••••@•••••

    Contact

  • Erasmus University Medical Center, Dr. Molewaterplein 40

    NOT_YET_RECRUITING

    Rotterdam, Netherlands

    Contact Email: •••••@•••••

    Contact

  • Malattie Aterotrombotiche, Azienda Ospedaliero Universitaria Careggi

    RECRUITING

    Florence, Italy

    Contact Email: •••••@•••••

    Contact

  • Medicina Interna, Ospedale Molinette, AOU Città della Salute e della Scienza

    NOT_YET_RECRUITING

    Torino, Italy

    Contact

  • Nefrologia e Emodialisi, Centro Aterosclerosi e Dislipidemie, Ospedale Bassini, ASST Nord Milano

    RECRUITING

    Cinisello Balsamo, Italy

    Contact Email: •••••@•••••

    Contact

  • U.O. Astanteria/MCAU AOU, Policlinico "Paolo Giaccone" di Palermo

    RECRUITING

    Palermo, Italy

    Contact Email: •••••@•••••

    Contact

  • U.O.C. di Medicina Interna, P.O. Nesima, ARNAS Garibaldi

    NOT_YET_RECRUITING

    Catania, Italy

    Contact Email: •••••@•••••

    Contact

  • UOC Clinica Medica I, AOU di Padova

    NOT_YET_RECRUITING

    Padova, Italy

    Contact Email: •••••@•••••

    Contact

  • Unité de Lipidologie et Prévention Cardiovasculaire, Centre de Compétence Dyslipidémies Rares (CEDRA), Service de Nutrition, Hôpital Pitié-Salpétriêre

    NOT_YET_RECRUITING

    Paris, France

    Contact Email: •••••@•••••

    Contact